The duodenal-jejunal bypass liner and the intragastric balloon are endoscopically deployed devices used in the treatment of obesity and diabetes. These devices use differing mechanisms of action, and concurrent use may lead to improved efficacy. Three obese patients who suffered from weight loss plateau with the liner had the intragastric balloon inserted concurrently. All 3 patients reported subsequent significant weight loss. None of the patients reported any symptom that indicate the interference between the devices. This is the first case series in humans of successfully combining 2 independent endoscopic bariatric therapies to overcome weight loss plateau in the primary treatment of obesity.
INTRODUCTION
Obesity is described by the World Health Organization as one of the most blatantly visible, yet most neglected health problems globally. 1 Endoscopic bariatric therapies (EBTs) have the potential to bridge the gap between dietary and lifestyle counseling and irreversible bariatric surgeries and offer as an efficacious and minimally invasive option. Currently available EBTs typically alter either gastric or small bowel physiology to elicit their effects.
The duodenal-jejunal bypass liner (EndoBarrier; GI Dynamics, Inc., Lexington, MA) is a Teflon-coated liner that is endoscopically placed in the duodenal bulb to create a barrier between chyme and the small bowel and remains in situ for a period of 12 months ( Figure 1 ). The putative mechanism of action is to induce malabsorption both by mechanical means and by delaying the admixture of chyme with biliopancreatic juices. The Orbera intragastric balloon (Orbera IGB, previously marketed as the BioEnterics Intragastric Balloon, BIB; Apollo Endosurgery, Inc., Irvine, CA) is a fixed-volume, silicone balloon that can be filled with up to 700 mL salinemethylene blue solution. The Orbera remains in situ for 6 months and provides gastric restriction and alters gastric emptying to modulate appetite and satiety in a reversible fashion. Figure 2 ). The patient then decided to undergo concurrent treatment with an Orbera IGB inserted while having the EndoBarrier in situ. In total, the patient had lost 20.0 kg when both devices were removed (DBMI 8.4 kg/m 2 , TBWL 23%, EWL 72.7%). However, following the uneventful deflation and retrieval of the balloon, the removal of the EndoBarrier liner resulted in a laceration within the duodenal bulb. The patient was then admitted to a hospital where she remained systemically well and was managed conservatively with intravenous antibiotics, gut rest, and intravenous fluids for 5 days before being discharged without sequelae. Two months after the removal, the patient elected to undergo insertion of a second IGB (Spatz3) for weight loss maintenance. The patient had Spatz3 implantation for 12 months and weight loss was maintained at 15.3 kg (DBMI 6.5 kg/m 2 , TBWL 17.7%, EWL 56.0%). The follow-up weight loss at 6 months after balloon removal was 17.1 kg (TBWL 19.7%).
CASE REPORT
Patient 2: Patient 2 is a 42-year-old man (baseline BMI 37.9 kg/ m 2 , EW 37.2 kg) and had a medical history of hyperlipidemia, sleep apnea, reflux esophagitis, and chronic back pain. The patient tolerated the EndoBarrier well and lost 16.4 kg (DBMI 5.7 kg/m 2 , TBWL 15.0%, EWL 44.1%) before reaching a weight loss plateau (Figure 2 ). The patient then underwent insertion of an Orbera IGB and lost 29.9 kg at removal of both devices (DBMI 10.4 kg/m 2 , TBWL 27.4%, EWL 80.8%). Then, the patient elected to undergo further intragastric balloon treatment. A Spatz3 IGB (500 mL) was inserted for weight loss maintenance. At month 21, after removal of the Spatz3 IGB (650 mL), the patient's weight loss was maintained at 31.3 kg (DBMI 10.8 kg/m 2 , TBWL 28.6%, EWL 84.3%). The follow-up weight loss at 6 months after balloon removal was 32.5 kg (TBWL 29.7%).
Patient 3: Patient 3 is a 50-year-old man (baseline BMI 37.6 kg/ m 2 , EW 40.3 kg). The patient had EndoBarrier and lost 12.4 kg (DBMI 3.9 kg/m 2 , TBWL 10.3%, EWL 30.8%) before reaching a weight loss plateau ( Figure 2 ). The patient then decided to undergo concurrent Orbera IGB therapy. In total, the patient lost 21.4 kg (DBMI 6.7 kg/m 2 , TBWL 17.8%, EWL 53.1%). Both the gastric balloon and the EndoBarrier were removed at 14 months after initial insertion without complication. The patient then elected to undergo insertion of a Spatz3 IGB for weight loss maintenance contemporaneously. At month 27, after removal of the Spatz3 IGB (700 mL), the patient's weight loss was maintained at 22.9 kg (DBMI 7.1 kg/m 2 , TBWL 19.0%, EWL 56.8%). The follow-up weight loss at 6 months after balloon removal was 20.5 kg (TBWL 17.0%).
DISCUSSION
We report the first 3 human cases of concurrent-multimodal, and consecutive, EBTs to address weight loss plateau, augment efficacy of the primary intervention, and maintain weight loss after device retrieval. These cases confirm the feasibility of concurrent multimodal EBT and provide pilot data on the augmented efficacy and reasonable safety profile of this approach. Importantly, the major complication encountered on removal of the EndoBarrier in patient A resolved without the need for surgery and is a well-documented complication of EndoBarrier, which has been previously attributed to the flawed design of the system. 2, 3 Given this event occurred after the removal of the Orbera, it is not considered to be the result of concomitant therapy. EndoBarrier was registered in Australia as a weight loss intervention at the time of this study.
Of interest, most patients were actively losing weight at the removal of both devices. The weight loss effects of multimodal EBT (TBWL 17-29%) appeared additive when compared against typical weight loss results since with either device alone (TBWL EndoBarrier 5%-10% and Orbera 12%). 2, [4] [5] [6] Although the application of a second solitary IGB did not seem to improve weight loss, it appears that such use may be an effective weight stabilization approach, although this requires further investigation. Furthermore, these patients received minimal adjunctive lifestyle intervention, which is now established as being a significant determinant of weight loss efficacy with all forms of EBT. 7 Previous research has found that patients experienced with intragastric balloons reported significantly less weight loss than those naïve to endoscopic bariatric procedures. 8 Given that EBTs are likely to become much more widespread due to the current obesity epidemic, we highlight the urgent need to study the implications of repeating EBTs, including anatomy change and relevant clinical outcomes. 9 This case series is of course limited in its interpretation owing to the retrospective nature and small number of cases. However, it firmly establishes the feasibility of a novel approach of combination and multimodal EBTs to augment weight loss efficacy and the management of weight loss plateau. Further studies are urgently needed to further establish the safety, optimal timing, and optimal combinations and/or sequences of EBTs, lifestyle therapy, and pharmacotherapy.
